Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control.

Iacobellis G, Goldberger JJ, Lamelas J, Martinez CA, Sterling CM, Bodenstab M, Frasca D

Nutrition, metabolism, and cardiovascular diseases : NMCD30 Aug 2024Cited by 9 (Europe PMC)

PMID39277531DOI10.1016/j.numecd.2024.08.019PepBankPUB-39277531

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialEfficacy outcome
In T2D/CAD patients undergoing CABG, intraoperative glucose was lower with liraglutide than placebo (146 ± 21 versus 160 ± 21 mg/dL; P < 0.01; ± measure unspecified).
In plain wordsIn T2D/CAD patients undergoing heart bypass surgery, glucose was lower with liraglutide than placebo.
Peptide
Liraglutide
Outcome
DecreaseIntra-operative glucose control
Study
n = 38
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4-12 weeksAs given in this study (human).
Measurements
Intraoperative glucose
146 mg/dL
liraglutide; reported ±21, uncertainty type unspecified; P < 0.01 versus placebo
Intraoperative glucose
160 mg/dL
placebo; reported ±21, uncertainty type unspecified
Source sentences
Summary
Liraglutide-treated patients had better intra-op glucose control than placebo (146 ± 21 vs 160 ± 21 mg/dl, p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
Report a problemFND-3927753105

Studies that did not test the peptide alone10

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneObservational studyMechanism
Across all T2D/CAD patients including placebo and liraglutide groups, miR16 was higher in coronary epicardial fat than subcutaneous fat (P < 0.01).
In plain wordsAcross T2D/CAD patients including placebo and liraglutide groups, miR16 was higher in coronary heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR16 expression in coronary epicardial adipose tissue
Study
n = 38
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
miR16, miR155 and miR181a were significantly higher in CORO-EAT and in LA-EAT than SAT (p < 0.01 and p < 0.05) in overall patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753106
03HumanNot a test of Liraglutide aloneObservational studyMechanism
Across all T2D/CAD patients including placebo and liraglutide groups, miR155 was higher in coronary epicardial fat than subcutaneous fat (P < 0.01).
In plain wordsAcross T2D/CAD patients including placebo and liraglutide groups, miR155 was higher in coronary heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR155 expression in coronary epicardial adipose tissue
Study
n = 38
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
miR16, miR155 and miR181a were significantly higher in CORO-EAT and in LA-EAT than SAT (p < 0.01 and p < 0.05) in overall patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753107
04HumanNot a test of Liraglutide aloneObservational studyMechanism
Across all T2D/CAD patients including placebo and liraglutide groups, miR181a was higher in coronary epicardial fat than subcutaneous fat (P < 0.01).
In plain wordsAcross T2D/CAD patients including placebo and liraglutide groups, miR181a was higher in coronary heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR181a expression in coronary epicardial adipose tissue
Study
n = 38
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
miR16, miR155 and miR181a were significantly higher in CORO-EAT and in LA-EAT than SAT (p < 0.01 and p < 0.05) in overall patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753108
05HumanNot a test of Liraglutide aloneObservational studyMechanism
Across all T2D/CAD patients including placebo and liraglutide groups, miR16 was higher in left atrial epicardial fat than subcutaneous fat (P < 0.05).
In plain wordsAcross T2D/CAD patients including placebo and liraglutide groups, miR16 was higher in left atrial heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR16 expression in left atrial epicardial adipose tissue
Study
n = 38
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
miR16, miR155 and miR181a were significantly higher in CORO-EAT and in LA-EAT than SAT (p < 0.01 and p < 0.05) in overall patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753109
06HumanNot a test of Liraglutide aloneObservational studyMechanism
Across all T2D/CAD patients including placebo and liraglutide groups, miR155 was higher in left atrial epicardial fat than subcutaneous fat (P < 0.05).
In plain wordsAcross T2D/CAD patients including placebo and liraglutide groups, miR155 was higher in left atrial heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR155 expression in left atrial epicardial adipose tissue
Study
n = 38
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
miR16, miR155 and miR181a were significantly higher in CORO-EAT and in LA-EAT than SAT (p < 0.01 and p < 0.05) in overall patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753110
07HumanNot a test of Liraglutide aloneObservational studyMechanism
Across all T2D/CAD patients including placebo and liraglutide groups, miR181a was higher in left atrial epicardial fat than subcutaneous fat (P < 0.05).
In plain wordsAcross T2D/CAD patients including placebo and liraglutide groups, miR181a was higher in left atrial heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR181a expression in left atrial epicardial adipose tissue
Study
n = 38
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
miR16, miR155 and miR181a were significantly higher in CORO-EAT and in LA-EAT than SAT (p < 0.01 and p < 0.05) in overall patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753111
08HumanNot a test of Liraglutide aloneObservational studyMechanism
In liraglutide-treated patients with T2D and CAD, miR16 expression was higher in coronary epicardial fat than subcutaneous fat (P < 0.01).
In plain wordsIn liraglutide-treated patients with T2D and CAD, miR16 was higher in coronary heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR16 expression in coronary epicardial adipose tissue
Study
n: not reported in source
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
miR16 and miR181-a were significantly higher in CORO-EAT than SAT (p < 0.01),
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753101
09HumanNot a test of Liraglutide aloneObservational studyMechanism
In liraglutide-treated patients with T2D and CAD, miR181a expression was higher in coronary epicardial fat than subcutaneous fat (P < 0.01).
In plain wordsIn liraglutide-treated patients with T2D and CAD, miR181a was higher in coronary heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR181a expression in coronary epicardial adipose tissue
Study
n: not reported in source
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
miR16 and miR181-a were significantly higher in CORO-EAT than SAT (p < 0.01),
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753102
10HumanNot a test of Liraglutide aloneObservational studyMechanism
In liraglutide-treated patients with T2D and CAD, miR155 expression was higher in left atrial epicardial fat than subcutaneous fat (P < 0.05).
In plain wordsIn liraglutide-treated patients with T2D and CAD, miR155 was higher in left atrial heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR155 expression in left atrial epicardial adipose tissue
Study
n: not reported in source
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
and miR155 and miR181a were higher in LA-EAT than SAT (p < 0.05) in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753103
11HumanNot a test of Liraglutide aloneObservational studyMechanism
In liraglutide-treated patients with T2D and CAD, miR181a expression was higher in left atrial epicardial fat than subcutaneous fat (P < 0.05).
In plain wordsIn liraglutide-treated patients with T2D and CAD, miR181a was higher in left atrial heart fat than under-skin fat.
Peptide
Liraglutide
Outcome
IncreasemiR181a expression in left atrial epicardial adipose tissue
Study
n: not reported in source
Comparator
Subcutaneous fat
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
and miR155 and miR181a were higher in LA-EAT than SAT (p < 0.05) in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 12-week randomized, double-blind, placebo-controlled study in 38 patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were started on either liraglutide or placebo for a minimum of 4 up to 12 weeks prior to coronary artery by-pass grafting (CABG).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3927753104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control.

Summary

Results from this study11

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms

Keywords